Harnessing albumin as a carrier for the delivery of anti-HIV drugs to the lymphatic system
Acta Biomaterialia · 2026-01 · 209 · 521-531
DOI: 10.1016/j.actbio.2025.11.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2026-01. Verfasst von Ziqian Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pharmacogenetics, Department of Pharmaceutical Science, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA; UPMC Hillman Can…. Hauptthemen laut MEDLINE: Anti-HIV Agents, Drug Carriers, Albumins, HIV Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
The persistence of human immunodeficiency virus (HIV) reservoirs in the lymphatic system remains a major obstacle to a complete cure, largely due to subtherapeutic concentrations of antiretrovirals (ARVs) in lymphatic tissues under current regimens. Developing innovative strategies to enhance ARV delivery to lymphatic tissues could therefore represent a paradigm shift in the pursuit of an HIV cure. Here, we describe a delivery strategy involving an Evans Blue (EB)-based prodrug conjugated with dolutegravir (DTG), a model ARV. This construct is designed to bind albumin with high affinity, facilitating transport to lymph nodes (LNs) via albumin-mediated trans-endothelial transcytosis. EB modification substantially improved the distribution of the conjugated molecule to LNs throughout the body, and the hEB-DTG prodrug increased DTG concentrations in LNs by up to 10-fold, suggesting a promising strategy for eradicating HIV reservoirs. STATEMENT OF SIGNIFICANCE: A major barrier to curing HIV infection is the persistence of viral reservoirs in lymphatic tissues, which current ARV therapies fail to eliminate due to poor drug penetration. To overcome this limitation, we developed a prodrug strategy that harnesses the natural trafficking of albumin to the lymphatic system. In this approach, ARVs are conjugated to EB, a high-affinity albumin-binding dye, to generate EB-ARV prodrugs that hijack albumin's endogenous transport pathways. After intravenous administration, these conjugates rapidly associate with circulating albumin, which mediates their transcytosis across endothelial barriers and directs their accumulation in lymph nodes and other lymphoid tissues. This strategy substantially enhances ARV exposure at the primary sites of viral persistence, representing a promising and potentially transformative approach for eradicating HIV reservoirs and advancing toward a functional cure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Pharmacogenetics, Department of Pharmaceutical Science, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
- Small Molecule Biomarker Core, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.
- Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Department of Geology and Environmental Science, University of Pittsburgh, Pittsburgh, PA, USA.
- Department of Microbiology, Howard University College of Medicine, WA, DC, USA.
- Center for Pharmacogenetics, Department of Pharmaceutical Science, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. Electronic…
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- NIAID NIH HHS
- NIH HHS
- University of Pittsburgh
- National Institutes of Health
Zitieren
APA
Zhang, Z., Huang, Y., West, R. E., Mahesh, D., Oberly, P. J., Li, S., Luo, Z., Chen, Y., Huang, H., Bain, D. J., Nolin, T. D., Bility, M. T., Mailliard, R. B., & Li, S. (2026). Harnessing albumin as a carrier for the delivery of anti-HIV drugs to the lymphatic system. Acta Biomaterialia, 209, 521-531. https://doi.org/10.1016/j.actbio.2025.11.017
Vancouver
Zhang Z, Huang Y, West RE, Mahesh D, Oberly PJ, Li S, et al. Harnessing albumin as a carrier for the delivery of anti-HIV drugs to the lymphatic system. Acta Biomaterialia. 2026;209:521-531. doi:10.1016/j.actbio.2025.11.017
BibTeX
@article{Zhang2026,
author = {Zhang, Ziqian and Huang, Yixian and West, Raymond E and Mahesh, Deepika and Oberly, Patrick Joseph and Li, Shichen and Luo, Zhangyi and Chen, Yuang and Huang, Haozhe and Bain, Daniel J and Nolin, Thomas D and Bility, Moses T and Mailliard, Robbie B and Li, Song},
title = {Harnessing albumin as a carrier for the delivery of anti-HIV drugs to the lymphatic system},
journal = {Acta Biomaterialia},
year = {2026},
volume = {209},
pages = {521--531},
doi = {10.1016/j.actbio.2025.11.017}
}
EUVIMED